Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease

Journal of Nephrology

Volumn 21, Issue 6, 2008, Pages 924-930

  Atamer, Aytaç ^a,g   Kocyigit, Yuksel ^b   Ecder, Sabahat Alisir ^c   Selek, Sahabettin ^d   Ilhan, Nevin ^e   Ecder, Tevfik ^f   Atamer, Yildiz ^b  

^a Diyarbakir Devlet Hastanesi   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d HARRAN UNIVERSITY   (Turkey)

^e FIRAT UNIVERSITY   (Turkey)

^f ISTANBUL UNIVERSITY   (Turkey)

^g Kent Plus   (Turkey)

Author keywords

Catalase; Homocysteine; Lipoproteins; Oxidative stress; Paraoxonase; Superoxide dismutase

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CATALASE; ERYTHROCYTE ENZYME; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UREA; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; MIDDLE AGED; PHOTOMETRY; PHYSIOLOGY; RETROSPECTIVE STUDY;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BODY MASS INDEX; CATALASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; OXIDATIVE STRESS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE;

EID: 62749156511     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Brady HB, Brenner BM. Pathogenetic mechanisms of glomerular injury. In: Fauci AS, Braunwald E, Isselbacker KJ, et al, eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998:1521-1536.
2. Pawlak K, Naumnik B, Brzosko S, Pawlak D, Mysliwies M. Oxidative stress-a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol. 2004;24:154-161.
3. Argani H, Ghorbani A, Rashtchizade N, Rahbaninobar M. Effect of lovastatin on lipid peroxidation and total antioxidant concentration in hemodialysis patients. Lipids Health Dis. 2004;3:6.
4. Gugliucci A, Mehlhaff K, Kinugasa E, et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta. 2007;377:213-220.
5. Paragh G, Seres I, Balogh Z, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron. 1998;80:166-170.
6. Witko-Sarsat V, Friedlander M, Capeillare-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-1313.
7. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
8. Ghorbanihaghjo A, Argani H, Rahbaninoubar M, Rashtchizadeh N. Effect of nandrolone decanoate on paraoxonase activity in hemodialysis patients. Clin Biochem. 2005;38:1076-1080.
9. Paragh G, Asztalos L, Seres I, et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron. 1999;83:126-131.
10. Jung HH, Choi DH, Lee SH. Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol. 2004;24:537-542.
11. Dantoine TF, Debord J, Charmes JP, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998;9:2082-2088.
12. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813-818.
13. Schrader M, Fahimi HD. Peroxisomes and oxidative stress. Biochim Biophys Acta. 2006;1763:1755-1766.
14. Drai J, Bannier E, Chazot C, et al. Oxidant and antioxidants in long-term hemodialysis patients. Farmaco. 2001;56:463-465.
15. Pawlak K, Pawlak D, Mysliwies M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem. 2005;38:700-705.
16. Shimomura H, Maehata E, Takamiya T, Adachi T, Komoda T. Blood extracellular superoxide dismutase levels in hemodialysis and its association with lipoprotein lipase mass and free fatty acid. Clin Chim Acta. 2003;328:113-119.
17. Sharma RP. Interactions of cisplatin with cellular zinc and copper in liver and kidney tissues. Pharmacol Res Commun. 1985;17:197-206.
18. Ajith TA, Nivitha V, Usha S. Zingiber officinale Roscoe alone and in combination with α-tocopherol protect the kidney against cisplatin-induced acute renal failure. Food Chem Toxicol. 2007;45:921-927.
19. Fu W, Dudman NPB, Perry MA, Young K, Wang XL. Interrelations between plasma homocysteine and intracellular S-adenosyl homocysteine. Biochem Biophys Res Commun. 2000;271:47-53.
20. Robles NR, Romero J, Gomez Casero L, Escola JM, Ramos JL, Sánchez Casado E. Hyperhomocysteinemia in patients with mild chronic renal failure. Eur J Intern Med. 2005;16:334-338.
21. Leskinen Y, Lehtimaki T, Loimaala A. Homocysteine and carotid atherosclerosis in chronic renal failure-the confounding effect of renal function. Atherosclerosis. 2004;175:315-323.
22. Lippi G, Tessitore N, Gammaro L. Cardiovascular risk factors in patients with chronic renal failure maintained on hemodialysis or continuous ambulatory peritoneal dialysis. Thromb Res. 2001;101:517-519.
23. Naruszewicz M, Klinke M, Dziewanowski K, Staniewicz A, Bukowska H. Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Metabolism. 2001;50:131-134.
24. Bostom AG, Kronenberg F, Jacques PF, et al. Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine critical impact of true glomerular filtration rate. Atherosclerosis. 2001;159:219-223.
25. Perna AF, Satta E, Lombardi C, Acanfora F, Ingrosso D, De Santo NG. Hyperhomocysteinemia and the cardiovascular disease of uremia. Nutr Res. 2004;24:839-849.
26. Baber U, Toto RD, De Lemos JA. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J. 2007;153:471-477.
27. Sattar N, Clark P, Greer IA, Shephard J, Packard CJ. Lipoprotein(a) levels in normal pregnancy and in pregnancy complicated with preeclampsia. Atherosclerosis. 2000;148:407-411.
28. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease, Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.
29. Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. J Lab Clin Med. 1975;85:337-341.
30. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-126.
31. Asakawa T, Matsushita S. Coloring conditions of thiobarbituric acid test for detecting lipid hydroperoxides. Lipids. 1980;15:137-140.
32. Furlong CE, Richter RJ, Seidel SL, Costa LG, Matulsky AG. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/ arylesterase. Anal Biochem. 1989;180:242-247.